Opus Genetics, Inc. (IRD) Stock Price & Analysis
Opus Genetics, Inc. (IRD) closed at USD 4.05 on Thursday, October 15, 2026, down 1.22% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 4.1; the Oct 15, 2026 session ranged USD 3.98–4.28 on volume of 2,897,746 shares. Market capitalization is $336.94M, with a 52-week range of USD 1.7–7.07 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IRD.md
Key facts (IRD)
- Analysts: Buy (mean 1.83 on a 1–5 scale) (18 analysts), mean target USD 13.41 (range 8–20).
- Total return with dividends: 1Y +101.5% vs S&P 500 +18.1%; 5Y -5.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD -0.15, revenue estimate $2.1M.
Analysts (IRD)
Consensus Buy (mean 1.83 on a 1–5 scale), 18 analysts; mean target USD 13.41 (low 8, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | Jones Trading | Target raised | Buy | $10 → $17 |
| 2026-10-02 | Chardan Capital | Maintained | Buy | $16 |
| 2026-09-10 | Wedbush | Target raised | Outperform | $10 → $13 |
| 2026-09-09 | Oppenheimer | Target raised | Outperform | $10 → $20 |
| 2026-09-09 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-09-09 | BTIG | Reiterated | Buy | $12 |
| 2026-09-09 | Chardan Capital | Target raised | Buy | $13 → $16 |
| 2026-08-07 | RBC Capital | Target lowered | Outperform | $10 → $9 |
| 2026-07-29 | TD Cowen | Initiated | Buy | |
| 2026-07-06 | Chardan Capital | Maintained | Buy | $13 |
| 2026-07-06 | BTIG | Reiterated | Buy | $12 |
| 2026-06-18 | Chardan Capital | Target raised | Buy | $11 → $13 |
Total return (dividends reinvested) (IRD)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +101.5% | -5.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +102.0% | -1.1% |
| Volatility (annualized) | 79.0% | 73.9% |
| Max drawdown | -49.2% (Apr 2026→Jul 2026) | -88.5% (May 2023→Apr 2025) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 4.05 |
|---|---|
| Change | ▼ 1.22% (down) |
| Previous Close | USD 4.1 |
| Open | USD 4.15 |
| Day Range | USD 3.98 – 4.28 |
| 52-Week Range | USD 1.7 – 7.07 |
| Volume | 2,897,746 shares |
| Market Cap | $336.94M |
| Exchange | NCM |
Technical Analysis (IRD)
Nexqual's technical model rates IRD "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.4 (neutral) |
| vs SMA50 | Below (USD 4.48) |
| MACD | -0.13 (negative) |
Analyst Ratings (IRD)
Wall Street analysts rate IRD "Buy" based on 18 analysts, with a mean price target of USD 13.41 (range USD 8–20), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 18 |
| Mean Target | USD 13.41 |
| High Target | USD 20 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 18 / 0 / 0 |
Earnings (IRD)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $2.08M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.08 vs est -0.16 ▲ beat |
| 2026-03-31 | USD -0.75 vs est -0.14 ▼ miss |
| 2025-12-31 | USD -0.21 vs est -0.1 ▼ miss |
| 2025-09-30 | USD -0.25 vs est -0.13 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (IRD)
| Total Revenue | $9.86M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -73.80% |
| Gross Margin | -291.85% |
| Operating Margin | -2182.78% |
| Profit Margin | +0.00% |
| ROE | -4796.52% |
| Current Ratio | 12.19 |
| Total Cash | $88.81M |
| Total Debt | $36.20M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (IRD)
Nexqual rates Opus Genetics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Strong — Revenue +29% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $89M cash vs $36M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$35M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -4797%, ROA -48.1% |
Ownership (IRD)
| Insider Ownership | +12.23% |
|---|---|
| Institutional Ownership | +69.30% |
| Shares Outstanding | 83.20M |
| Float | 64.68M |
| Short % of Float | +16.45% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (IRD)
Opus Genetics, Inc. is led by George Magrath M.B.A., M.D., M.S. (age 40), CEO & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| CEO & Director | George Magrath M.B.A., M.D., M.S. (age 40) |
|---|---|
| President & Director | Benjamin R. Yerxa (age 59) |
| Chief Operating Officer | Joseph K. Schachle (age 60) |
| Chief Scientific & Development Officer | Ashwath Jayagopal (age 42) |
| CFO & Principal Accounting Officer | Robert E. Gagnon (age 51) |
Major Backers & Investors (IRD)
Notable institutional backers of Opus Genetics, Inc. include Caligan Partners, LP, Adage Capital Partners GP L.L.C., Bios Capital Management, LP , according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Caligan Partners, LP | 7.35% |
| Adage Capital Partners GP L.L.C. | 7.3% |
| Bios Capital Management, LP | 4.46% |
| Balyasny Asset Management LP | 3.74% |
| Nantahala Capital Management, LLC | 3.7% |
| Boxer Capital Management, LLC | 3.41% |
| Trails Edge Capital Partners, LP | 3.32% |
| Millennium Management | 2.79% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.08% |
| BlackRock | 6.21% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt